- Home
- PRSU vs AVBP Comparison
PRSU vs AVBP Comparison
Compare PRSU & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRSU
- AVBP
- Stock Information
- Founded
- PRSU 1926
- AVBP 2021
- Country
- PRSU United States
- AVBP United States
- Employees
- PRSU N/A
- AVBP N/A
- Industry
- PRSU Business Services
- AVBP
- Sector
- PRSU Consumer Discretionary
- AVBP
- Exchange
- PRSU Nasdaq
- AVBP NYSE
- Market Cap
- PRSU 876.5M
- AVBP 879.2M
- IPO Year
- PRSU N/A
- AVBP 2024
- Fundamental
- Price
- PRSU $37.65
- AVBP $27.07
- Analyst Decision
- PRSU Buy
- AVBP Strong Buy
- Analyst Count
- PRSU 1
- AVBP 4
- Target Price
- PRSU $50.00
- AVBP $38.00
- AVG Volume (30 Days)
- PRSU 263.0K
- AVBP 143.3K
- Earning Date
- PRSU 03-04-2025
- AVBP 03-04-2025
- Dividend Yield
- PRSU N/A
- AVBP N/A
- EPS Growth
- PRSU 58.18
- AVBP N/A
- EPS
- PRSU 1.06
- AVBP N/A
- Revenue
- PRSU $1,399,418,000.00
- AVBP N/A
- Revenue This Year
- PRSU $3.17
- AVBP N/A
- Revenue Next Year
- PRSU N/A
- AVBP N/A
- P/E Ratio
- PRSU $38.25
- AVBP N/A
- Revenue Growth
- PRSU 17.10
- AVBP N/A
- 52 Week Low
- PRSU $29.46
- AVBP $14.35
- 52 Week High
- PRSU $47.49
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- PRSU N/A
- AVBP 49.67
- Support Level
- PRSU N/A
- AVBP $25.89
- Resistance Level
- PRSU N/A
- AVBP $28.12
- Average True Range (ATR)
- PRSU 0.00
- AVBP 1.48
- MACD
- PRSU 0.00
- AVBP -0.06
- Stochastic Oscillator
- PRSU 0.00
- AVBP 33.69
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize team's deep drug development experience to maximize the potential of lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.